Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANHEART (H-HeFT and Met-HeFT)
2024-514212-27-00Phase 3Completed
- Sponsor
- Aarhus University Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of isosorbide dinitrate and metformin in heart failure (HF), type 2 diabetes mellitus (T2DM) and insulin resistance (IR) (4 arms), sponsored by Aarhus University Hospital. Primary endpoints: H-HeFT primary endpoint and Met-HeFT primary endpoint. Started Sep 2024; status: completed.
02
Drugs
isosorbide dinitratemetformin
03
Conditions
heart failure (HF)type 2 diabetes mellitus (T2DM)insulin resistance (IR)
Beyond the preview
Go deeper on 2024-514212-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514212-27-00.